Objective. The risk of AS is associated with genomic variants related to antigen presentation and specific cytokine signalling pathways, suggesting the involvement of cellular immunity in disease initiation/progression. The aim of the present study was to explore the repertoire of TCR sequences in healthy donors and AS patients to uncover AS-linked TCR variants.
Introduction
SpAs are a group of diseases with similar clinical and genetic features, which includes AS, PsA, enteropathic arthritis, undifferentiated SpA and ReA. Strong linkage with certain alleles of genes involved in the antigen-presenting pathway (HLA-B, ERAP1 and ERAP2; reviewed by Brown et al. [1] ) underlies the arthritogenic peptide hypothesis of AS and other HLA-B*27-associated disease initiation [2] . The hypothesis suggests expansion of selfreactive T cell clones triggered by cross-reaction with putative pathogen-derived peptide presented on HLA-B*27. The similarity in clinical manifestations and association of certain MHC alleles with increased disease risk might indicate a similar or identical structure of the putative antigen(s) recognized by the self-reactive T cell clones. This, in turn, implies that the expanded T cell clones, specific to the antigen, might have a similar structure of the antigenrecognizing domain of the TCR. Several studies have revealed the presence of T cell clones with highly homologous TCR identified in peripheral blood and synovial fluid of different patients with ReA [35] . However, until the development of high-throughput sequencing, T cell repertoire analysis was restricted to comparisons of tens to hundreds TCRs between several patients.
Recently, Faham et al. [6] have used high-throughput sequencing-based profiling of TCR repertoires from a large collection of peripheral blood (PB) samples from AS patients and healthy donors and identified a CDR3 motif similar to the one previously described for ReA.
Here, we report the results of our independent study designed to search for T cell clonotypes linked with AS. We applied deep TCR profiling with unique molecular identifier (UMI)-based quantification and error correction [7] to peripheral whole blood samples of 25 AS patients and 107 healthy donors and identified on average $200 000 TCR b clonotypes per donor. Using a new algorithm based on probabilistic assessment of clonal sharing between donors, we identified the group of CD8 + T clonotypes with highly similar TCR b shared almost exclusively between AS patients. The TCR structure of the clonotypes confirms the findings of Faham et al. [6] . We also demonstrate the presence and enrichment of the clonotypes in SF of inflamed joints of all HLA-B*27 + AS patients studied, suggesting their involvement in pathogenesis.
Methods

Donors and samples
For the present study, PB samples were obtained from 25 AS patients (24 HLA-B*27 + and 1 HLA-B*27 À ; details of the patient cohorts, including age, sex and treatment, are provided in supplementary Anti-PE MicroBeads (Myltenyi, Bergisch Gladbach, Germany) were used. Total RNA from sorted cells was isolated using RNAeasy Mini kit (Qiagen, Venlo, The Netherlands) and completely used for TCR library preparation. UMI-tagged 5 0 -RACE TCR b cDNA libraries were prepared according to the previously described general protocol [7] , with a double-end sample barcoding strategy. Details of the protocol with implementation of double barcoding, including consumables, oligonucleotides, RT and PCR conditions, were described earlier [9] . Libraries were sequenced with Illumina HiSeq 2000/2500 (Illumina, San Diego, CA, USA) in 100 + 100 pair-end mode.
Raw sequencing data obtained for the present study are available in the Sequence Read Archive database (SRP111372).
Sequencing data analysis and statistical methods
Raw sequencing data were pre-processed using MiGEC software [11] . To exclude erroneous clonal sharing that resulted from cross-sample contamination, we used a double-indexing strategy of library preparation with introduction of the first sample-specific barcode directly during cDNA synthesis. All reads with improper pairs of sample barcodes were discarded before repertoire reconstruction. Reads containing UMIs that have been sequenced only once were also discarded, ensuring that all TCR b cDNA molecules that passed to further analysis were sequenced at least twice. This allowed us essentially to reduce the number of erroneous reads, comprising sequencing and PCR errors, before further steps of UMI-based reads error correction that are included in the MiGEC pipeline. TCR b CDR3 sequences were then extracted using MiTCR software with ETE mode for advanced correction of erroneous clonotypes [12] . Further TCR repertoire analysis was performed using the tcR R-package [13] and R programming language [14] .
TCR clonotypes were assigned to the CD4 + or CD8 + T cell subpopulation based on detection of the corresponding TCR b nucleotide sequence in repertoire data obtained for separated CD4 + or CD8 + T cell samples isolated from the same PBMC sample. The ambiguities were solved using the abundance ratio threshold: clonotypes at least 10 times more abundant in one cell subset compared with another were attributed to the first subset; clonotypes with a lower ratio were attributed as undefined.
Fisher's exact test with the BenjaminiHochberg correction was used to calculate P-values for comparisons of clonotype frequency between cohorts or clonotype abundance.
In the analysis of clonal recombination probability, P-values for clonotype sharing were calculated using the density of log 10 rearrangements distribution (assuming normal distribution) for clonotypes shared by a certain number of donors (i.e. for clonotypes shared between four donors, five donors, etc.). To obtain a better estimate of distribution parameters, we pooled together clonotypes shared between more than seven individuals (independently of the disease status of the donors who shared the clonotypes), to obtain 530 observations in each bin. The P-value threshold was set up at <0.001, and each clonotype below the threshold was considered as having significantly higher sharing than could be expected based on its recombination probability.
Results
T cell repertoire profiling strategy
Study of T cell clonal sharing between donors could be biased dramatically by cross-contamination between samples and sequencing errors, affecting the detection of clones in samples. Here, to study T cell repertoires of AS patients and healthy donors we used our previously published protocol [7, 9] , which relies on dual indexing to eliminate cross-sample contamination and UMI for correction of PCR and sequencing errors. Importantly, tagging of each TCR b mRNA molecule with UMI allowed us to count the number of TCR mRNA molecules passed to the analysis and to estimate the abundance of T cell clonotypes identified [11, 15, 16] .
TCR profiling depth also can influence the detection of T cell clones in a sample. For whole blood samples, a comparable TCR repertoire profiling depth was reached for both cohorts: on average we analysed 180 591 and 206 162 unique TCR beta mRNA molecules for the samples from AS patients and HLA-B*27 + healthy donors, respectively. Even, greater averaged depth was achieved for blood samples of the donors in whole control cohort of 107 healthy donors (see next subsection; supplementary Table S2 , available at Rheumatology online).
Discovery of AS-related T cell clonotypes using assessment of VDJ recombination probability T cell clonotype sharing between samples derived from different donors depends on several sequential events: generation of the particular TCR during VDJ recombination, successful selection of the clone in the thymus and further clonal expansion in the periphery [17] . It can be stated that TCR variants with a relatively high probability of generation will be shared between a higher number of donors compared with those having a lower probability of generation, irrespective of antigen specificity and involvement in the immune response.
On the contrary, clonal expansion of T cells specific for a particular antigen increases their chance of getting into a sample and, thus, the probability of their detection in the donor. Hence, the immune response against a particular antigen shared between individuals, especially in a similar MHC context, increases the in-cohort detection frequency (i.e. sharing between donors) of identical or highly homologous TCR variants specific for this antigen [18, 19] . Thus, the expansion can increase sharing of the clonotypes with a relatively low probability of generation.
Considering this, we applied a new approach based on probabilistic assessment of the sharing of each TCR b clonotype between donors to find the clonotypes that are shared between a higher number of donors than could be expected in the absence of clonal expansion.
As the first step, to provide a rough estimate of clonal sharing, we analysed the presence of 54 000 TCR b clonotypes that were shared between at least three AS patients (i.e. clonotypes, shared between 510% of patients) in PB T cell repertoires of healthy donors (control cohort, n = 107; combined data obtained using same TCR profiling technique from the present study and three others [810]). We found only one clonotype, TRBV9CAS SVGLYSTDTQYFTRBJ2-3, with significantly higher sharing in AS patients compared with healthy donors (supplementary Table S3 , available at Rheumatology online).
To confirm that unusual sharing of the TRBV9CA SSVGLYSTDTQYFTRBJ2-3 clonotype between AS patients was attributable to clonal expansion and to increase the analytical power to search for other clonotypes overrepresented between patients, we estimated the probability of generation of CDR3 b amino acid sequences encoded by TRBV9TRBJ2-3 rearrangements for all clonotypes found in the data. We extended the statistical model of TCR generation originally published by Murugan et al. [20] by adding the Monte-Carlo approach; the probability of generation of a given TCR amino acid sequence was estimated as the average number of corresponding nucleotide sequences generated in silico.
We generated 2 Â 10 9 TRBV9TRBJ2-3 TCR rearrangements, out of which 1.2 Â 10 7 corresponded to 335 TRBV9TRBJ2-3 CDR3 amino acid sequences shared between at least any four donors from the cohort: 25 AS https://academic.oup.com/rheumatology patients, 7 HLA-B*27 + and 7 HLA-B*27 À healthy donors. As expected, the number of donors positive for each particular clonotype was roughly proportional to the number of in silico rearrangements that resulted in the corresponding CDR3 amino acid sequence, thus demonstrating that clonotypes with a higher probability of generation have higher sharing between donors (Fig. 1) .
Notably, eight TCR b clonotypes had a higher frequency of detection among donors than could be expected by chance based on their generation probability (P < 0.001; dashed line in Fig. 1 ), suggesting that their expansion was driven by a common antigen. Seven of them had a highly similar sequence and were found exclusively in AS patients. Of these clonotypes, the greatest sharing between patients was observed for the previously detected TRBV9CASSVGLYSTDTQYFTRBJ2-3. Consistent with the estimated relatively low probability of generation and thus low probability of being shared between donors, each of the clonotypes was found in PB samples of 44 donors in the whole control cohort of 107 healthy individuals ( Fig. 2A ; supplementary Fig. S1 , available at Rheumatology online).
PB samples from 15 of 25 AS patients were positive for at least one of the eight clonotypes discovered. Five of the clonotypes were previously published in several studies of SF and blood samples from patients with ReA [35] . Clonotypes CASSVGLFSTDTQYF, CASSVGLYSTDTQYF and CASSVGVYSTDTQYF from our study belong to the motif that was recently discovered in blood samples of AS patients [6] . Occurrence of the clonotypes matching the motif was very similar for the two independent studies; the proportion of positive patients was 0.56, compared with 0.57 in our cohort. Thus, in the present study we independently discovered a group of similar TCR b clonotypes identical to or closely resembling the ones published previously for ReA and AS.
By sequencing of CD8 + and CD4 + T cell subpopulations isolated from the PB of eight AS patients from our cohort, we attributed the AS-related clonotypes discovered in our study to the subpopulations. Seven of the eight clonotypes were detected exclusively in CD8 + cell samples, and CASSVGGFGDTQYF was found only in one sample of CD4 + cells (Fig. 1) .
Abundance of the AS-related clonotypes in peripheral blood of patients and healthy donors Involvement of T cell clones in inflammation should lead to clonal expansion and, thus, to increased number of cells with a particular TCR in the donor's blood. To perform quantitative analysis of TCR b repertoires, we normalized raw sequencing data using UMI. The normalization minimizes the impact of PCR bias on the estimation of clonal abundances [16] . Surprisingly, all eight clonotypes had a relatively low abundance in PB of patients despite their significant sharing in the AS cohort ( Fig. 2A) . The highest and lowest concentrations in PB observed for the ASrelated clonotypes were $0.006 and $0.00008%, respectively. For comparison, the average proportion of top 1 T cell clonotypes in AS PB samples was 3.86% (interquartile range: 2.7%). Based on previous estimation of the efficiency of the TCR profiling technology used, most of sequenced unique UMI-labelled TCR b mRNA molecules represent distinct T cells [8] . This means that the number of T cells with the most expanded AS-related TCR b was $6/100 000 PB T cells of the patient. Low abundance of T cell clones in peripheral blood might account for their absence in some samples, because of sampling or insufficiency of repertoire analysis depth. To increase the depth and test the presence of the AS-related clonotypes in PB of healthy HLA-B*27 + donors we sequenced repertoires of FACS-sorted TRBV9 + T cells from six donors analysed earlier in this study and one additional HLA-B27 + healthy individual. For each donor, we sorted 535 000 TRBV9 + CD8 + T cells and 550 000 TRBV9 + CD8 À T cells, thus obtaining a 10-fold increase in
FIG. 1 Identification of AS-related T cell clonotypes based on probabilistic model of TCR rearrangement
Each dot represents a unique TRBV9TRBJ2-3 amino acid TCR b sequence shared between the given number of any donors (x-axis) from the cohort of 25 AS patients, 7 HLA-B*27 + and 7 HLA-B*27 À healthy donors. Clonotypes found exclusively in AS patients are shown in black. On the y-axis, the log 10 of in silico-produced rearrangements corresponding to the CDR3 amino acid sequences is shown. The dashed line represents the threshold of significance for the clonotype sharing deviation above the expected level based on the probability of recombination (P < 0.001). The right panel shows the eight TCR b clonotypes unusually shared between donors. These clonotypes are enriched between AS patients compared with healthy controls. *Previously published ReA and AS clonotypes. **Published with V b segment TRBV13. the number of analysed TRBV9
+ cells compared with the whole blood sequencing (where we analysed $6700 TRBV9 + cells on average for both the AS cohort and HLA-B27 + healthy donors). Of the eight AS-related clonotypes discovered, we found four in three donors in sum, and only two donors had the clonotypes in the CD8 + T cell subset. The abundance of the clonotypes normalized for whole blood was much lower than in PB samples of AS patients (Fig. 2B ). This finding indicates that AS-related clonotypes are also present in the PB of some healthy donors, albeit at extremely low frequencies.
We also compared the TCR profiling depth for samples of AS patients where we observed at least one of the eight clonotypes (positive) with the ones where no AS-related clonotypes were detected (negative). The number of sequenced TCR cDNA molecules with the TRBV9 TRBJ2-3 combination was higher for positive samples (Wilcoxon rank sum test P < 0.002), and no difference was observed in the proportion of this combination in the TCR repertoire between positive and negative samples (supplementary Fig. S2 , available at Rheumatology online). This result indicates that the proportion of negative samples in the AS cohort could be lowered with the increase in TCR profiling depth. Bystander activation of T cells in an inflammatory milieu may lead to the presence in the repertoire of an inflamed site of T cell clones activated without TCR engagement and, thus, not related to antigens represented in the site [21, 22] . Considering this, we analysed clonotype sharing between samples from HLA-B*27 + patients, suggesting that the group of shared clonotypes should be enriched by those recognizing site-specific antigens, whereas the repertoire of bystander T cells should be more diverse between patients. Owing to technical reasons, for patient D the TCR sequencing data were available only for TRBV9 + SF T cells, and this sample was excluded from analysis of clonal sharing and abundance. We identified 10 00040 000 TCR b amino acid variants for each CD8 + SF T cell sample from HLA-B*27 + patients, but only 195 clonotypes were shared between at least two samples. Most of the shared clonotypes had TRBV9TRBJ2-3 rearrangement, and six of the eight TRBV9TRBJ2-3 clonotypes formed a group with a highly similar amino acid CDR3 sequence ( Fig. 3A; supplementary Table S4 , available at Rheumatology online). This group includes the five ASrelated clonotypes discovered in PB samples and one additional variant, TRBV9CASSAGLYSTDTQYFTRBJ2-3, which was shared between all three CD8 + SF samples of HLA-B*27 + patients. The clonotype was found in only one unmatched PB sample of AS donors and was not detected in the PB of any of the healthy donors studied.
We also compared the difference in abundance of the AS-related clonotypes between the SF and PB samples of https://academic.oup.com/rheumatology same donors. Each of the clonotypes had a significantly higher abundance in SF compared with PB in at least one of the three sample pairs studied (Fig. 3B) , suggesting their targeting to the inflamed tissue. Despite the fact that the AS-related clonotypes were enriched in the inflamed joint, they were not the most expanded clonotypes in SF, being ranked below 540 other clonotypes by clonal size in all of the three samples.
Discussion
By combining high-throughput TCR sequencing and a new computational approach for analysis of the sharing of T cell clonotypes, which relies on estimation of the probability of TCR b VDJ rearrangement, we were able to discover a group of highly similar TCR clonotypes that were significantly overrepresented in AS patients [found in 15 of 25 patients (60%)]. For these clonotypes, the in silico estimated generation probability of TCR b appeared to be relatively low. In good agreement with that result, we found the clonotypes in sum in only 12 of 107 PB samples from the whole cohort of healthy donors (11.2%). Importantly, seven out of the eight clonotypes were not detected in PB of HLA-B27 + healthy donors with comparable analysis depth. Furthermore, these seven clonotypes were detected in SF from an inflamed joint of HLA-B*27 + AS donors (n = 4). Higher abundance of the clonotypes in SF compared with matched PB samples suggests targeting of T cell clones with such TCR b chains into the site of inflammation. The CD8 + status of these clonotypes was confirmed by sequencing of separated T cell subsets. After analysis of the SF samples, we added to the group of AS-related clonotypes one additional clonotype with a highly similar CDR3. The clonotype was detected in the CD8 + subset of all HLA-B*27 + SF samples, but in only one PB sample. Five of the AS-related clonotypes were reported previously in SF and PB of patients with ReA [35] , and four of them were recently discovered in PB of AS patients [6] . Three of our clonotypes matched the most frequent AS motif from the study by Faham et al. [6] . The proportion of PB samples positive for the clonotypes was almost identical in our AS cohort. Thus, in the present study we demonstrate the independent discovery of T cell clonotypes associated with positive AS status, supporting the recent discovery [6] in an independent cohort of patients. We also support involvement of the clonotypes in AS pathogenesis by demonstrating their presence and enrichment in an inflamed joint in AS patients. The advanced algorithm, based on estimation of the probability of generation for shared clonotypes, allowed us to find the TCR motif characteristic for AS patients, using a much smaller cohort of donors compared with the study of Faham et al. [6] . This demonstrates the power of the algorithm to search for clonotypes specifically enriched between samples even if an adequate control is not possible.
The higher frequency of detection of the AS-related clonotypes in the repertoires of AS patients compared with healthy individuals, in combination with the relatively low probability of generation of such TCR b, reflects expansion of the clonotypes in peripheral blood of AS patients. Higher abundance of the clonotypes in AS patients was confirmed by direct comparison between the PB samples from patients and healthy donors. Several of these clonotypes were detected in the PB of HLA-B*27 + healthy donors only after a substantial increase of the depth of analysis of the repertoire, showing that the difference between healthy and AS individuals resides in expansion of the AS-related clonotypes rather than in the presence of such T cells in the repertoire. The group of AS-related clonotypes was initially discovered independently of their CDR3 amino acid sequence; however, the clonotypes appeared to have similar or identical amino acids in the same positions of CDR3 (Fig. 4A ) that can be described by the amino acid motif. The sequences have a greater similarity if we consider the physical and chemical properties of their CDR3 amino acids, e.g. hydrophilicity [23] and average volume [24] (Fig. 4B and C) . This suggests similar or identical antigen specificity for the clonotypes matching the TCR b motif. This is also supported by simultaneous expansion of several clonotypes with such a motif observed in each positive PB or SF sample. Potential HLA-B*27 restriction of the clonotypes also supports the suggestion. Discovery of the AS-related clonotypes with assumed similar specificity reinforces the arthritogenic peptide hypothesis of AS initiation; however, future studies with the aim of determining the antigen specificity of these clonotypes are necessary to clarify their relationship to the disease.
The advanced TCR profiling technique with UMI-based normalization allowed us to demonstrate that the discovered AS-related clonotypes had a relatively low abundance in PB and, more importantly, were enriched but not the most abundant in SF during inflammation. Based on this, it can be speculated that these T cell clones are probably not the key players in the late stages of the disease. The high similarity of the CDR3 amino acid sequence between clonotypes detected in the SF of early ReA and AS patients, together with HLA-B*27 restriction and the clinical similarity between AS and ReA [25] , suggests that the mechanism of initiation of AS might be similar to ReA at least in some patients, and these clonotypes could play an active role during the initial stages of AS.
Although the AS-related clonotypes were enriched in AS patients, we were unable to detect them in $40% of our AS patients. The fraction of donors with no AS-related clonotypes is similar to the one reported by Faham et al. [6] . We suggest that insufficient depth of repertoire sequencing and/or the presence of additional TCR motifs (not linked to TRBV9, or even restricted to the TCR a chain) could be among the reasons explaining our limited recall.
Given the present level of knowledge, it is impossible to exclude an alternative explanation for our results, namely the hypothesis that the expansion of the identified ASrelated clonotypes is a consequence of inflammatory joint damage during progression of ReA or AS in HLA-B27 + donors. Thus, further studies, designed to test the involvement of the identified TCR b clonotypes in the pathogenesis of AS and other SpAs, promise to shed light on the mechanisms of initiation of SpA.
